Halozyme Therapeutics, Inc.
HALO
NASDAQ·Healthcare·Biotechnology·Mkt cap $13.1B
$110.19
▼ -0.51%
P/E
31.30
Mkt Cap
$13.1B
52-Wk Range
$61.23–$111.15
52-Week Range
$61.23 - $111.15
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 45.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary ENHANZE technology with strong patent protection
- Strategic partnerships with top-tier pharmaceutical companies
- Recurring royalty-based revenue model with low incremental costs
- Expanding addressable market across oncology, immunology, and rare diseases
Bear Case
1 risk
- Average volatility.
Growth
Moderate growth ahead
Expansion of subcutaneous formulations across partner drug portfolios
Value
Undervalued - trading well below Biotech & Therapeutics peers
Momentum
Hot
+55.8% over 3m
Quality
Excellent
Excellent business quality
Dividend
None
No dividend
Smart-money signal
Who's buying HALO right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 2, 2026
AUG 6, 2026
Reported EPS of $2.28 vs $1.79 consensus (+27.4% surprise). Revenue of $481.0M vs $402.3M expected (+19.6%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+27.4%
Revenue trend · last 8Q
—
—
+35%
+41%
+22%
+52%
+42%
+48%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$290.1M
$298.0M
$264.9M
$325.7M
$354.3M
$451.8M
$376.7M
$481.0M
Margins · last 8Q
Gross
83.5%
Operating
59.8%
Profit
47.8%
Wall Street consensus
6 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Sep 2, 2026
vs Industry
How HALO stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related